Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immunocompetent Allogeneic Recipients
Induced pluripotent stem cells (iPSCs) are promising candidates for regenerative cell-based therapies. Because autogenic iPSCs are not available for acute treatment procedures, allogeneic strategies have to be developed which evade immune rejection. We showed in this study that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: X. Hu, T. Deuse, A. Gravina, D. Wang, G. Tediashvili, C. De, W. Thayer, A. Wahl, V. Garcia, H. Reichenspurner, M. Davis, L. Lanier, S. Schrepfer Tags: (418) Source Type: research
More News: Cardiology | Genetics | Heart | Heart Transplant | Lung Transplant | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants